Creative Medical Technology's BioDefense stake reaches 80% via related-party stock purchase

Creative Medical Technology Holdings, Inc. entered into a Stock Purchase Agreement on September 24, 2026 with Creative Acquisition Corp. (CAC), under which the Company purchased 4,000,000 shares of common stock of BioDefense, Inc. from CAC for an aggregate purchase price consisting of $200,000 in cash and 1,000,000 shares of the Company's common stock.¹ The agreement was disclosed in an 8-K signed and dated September 25, 2026, one day after the transaction's effective date.

As a result of the deal, the Company now owns 16,000,000 shares of BioDefense common stock, constituting 80% of the outstanding shares of common stock of BioDefense, while CAC owns 4,000,000 shares of BioDefense common stock, constituting 20% of the outstanding shares.¹

The transaction involves overlapping leadership. Timothy Warbington, the President and Chief Executive Officer of Creative Medical, is also the Chairman and Chief Executive Officer of CAC and indirectly owns all of its outstanding shares of capital stock.¹

On the payment side, the shares of Creative Medical common stock issued to CAC under the Purchase Agreement were issued in a private placement pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended.¹ The filing also reports this issuance under Item 3.02 covering unregistered sales of equity securities, with that disclosure incorporating the Item 1.01 information by reference.¹

The Stock Purchase Agreement is included as Exhibit 10.1 to the filing. The report was signed by Timothy Warbington as Chief Executive Officer on September 25, 2026.¹